Cargando…
Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208895/ https://www.ncbi.nlm.nih.gov/pubmed/35747845 http://dx.doi.org/10.1097/HS9.0000000000000729 |
| _version_ | 1784729812401651712 |
|---|---|
| author | Kutsch, Nadine Pallasch, Christian Decker, Thomas Hebart, Holger Chow, Kai Uwe Graeven, Ullrich Kisro, Jens Kroeber, Alexander Tausch, Eugen Fischer, Kirsten Fink, Anna-Maria Wendtner, Clemens-Martin Ritgen, Matthias Stilgenbauer, Stephan Zhang, Danjie Li, Biao Jürgensmeier, Juliane M. Rajakumaraswamy, Nishanthan Bhargava, Pankaj Hallek, Michael Eichhorst, Barbara |
| author_facet | Kutsch, Nadine Pallasch, Christian Decker, Thomas Hebart, Holger Chow, Kai Uwe Graeven, Ullrich Kisro, Jens Kroeber, Alexander Tausch, Eugen Fischer, Kirsten Fink, Anna-Maria Wendtner, Clemens-Martin Ritgen, Matthias Stilgenbauer, Stephan Zhang, Danjie Li, Biao Jürgensmeier, Juliane M. Rajakumaraswamy, Nishanthan Bhargava, Pankaj Hallek, Michael Eichhorst, Barbara |
| author_sort | Kutsch, Nadine |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9208895 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92088952022-06-22 Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia Kutsch, Nadine Pallasch, Christian Decker, Thomas Hebart, Holger Chow, Kai Uwe Graeven, Ullrich Kisro, Jens Kroeber, Alexander Tausch, Eugen Fischer, Kirsten Fink, Anna-Maria Wendtner, Clemens-Martin Ritgen, Matthias Stilgenbauer, Stephan Zhang, Danjie Li, Biao Jürgensmeier, Juliane M. Rajakumaraswamy, Nishanthan Bhargava, Pankaj Hallek, Michael Eichhorst, Barbara Hemasphere Letter Lippincott Williams & Wilkins 2022-05-25 /pmc/articles/PMC9208895/ /pubmed/35747845 http://dx.doi.org/10.1097/HS9.0000000000000729 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| spellingShingle | Letter Kutsch, Nadine Pallasch, Christian Decker, Thomas Hebart, Holger Chow, Kai Uwe Graeven, Ullrich Kisro, Jens Kroeber, Alexander Tausch, Eugen Fischer, Kirsten Fink, Anna-Maria Wendtner, Clemens-Martin Ritgen, Matthias Stilgenbauer, Stephan Zhang, Danjie Li, Biao Jürgensmeier, Juliane M. Rajakumaraswamy, Nishanthan Bhargava, Pankaj Hallek, Michael Eichhorst, Barbara Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia |
| title | Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia |
| title_full | Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia |
| title_fullStr | Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia |
| title_full_unstemmed | Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia |
| title_short | Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia |
| title_sort | efficacy and safety of tirabrutinib and idelalisib with or without obinutuzumab in relapsed chronic lymphocytic leukemia |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208895/ https://www.ncbi.nlm.nih.gov/pubmed/35747845 http://dx.doi.org/10.1097/HS9.0000000000000729 |
| work_keys_str_mv | AT kutschnadine efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT pallaschchristian efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT deckerthomas efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT hebartholger efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT chowkaiuwe efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT graevenullrich efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT kisrojens efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT kroeberalexander efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT tauscheugen efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT fischerkirsten efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT finkannamaria efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT wendtnerclemensmartin efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT ritgenmatthias efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT stilgenbauerstephan efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT zhangdanjie efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT libiao efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT jurgensmeierjulianem efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT rajakumaraswamynishanthan efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT bhargavapankaj efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT hallekmichael efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia AT eichhorstbarbara efficacyandsafetyoftirabrutinibandidelalisibwithorwithoutobinutuzumabinrelapsedchroniclymphocyticleukemia |